• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Beyond the Pharma Horizon: CPhI's 2015 Market Report, Part III


October 28, 2015.

Part 3 of CPhI’s annual report, in which experts outline key trends and issues for the pharmaceutical industry, is now available, featuring expert analysis from Dilip Shah, CEO of Vision Consulting Group; Vivek Sharma, CEO of Piramal Enterprise, Pharma Solutions; Prabir Basu, manufacturing, operational excellence and cGMP consultant, and former head of the US National Institute for Pharmaceutical Training and Education (NIPTE); and Alan Shepperd, IMS Health’s global generics thought leader principal.

They experts topics from macroeconomic trends and the impact of mega trade pacts on pharmaceutical markets to growth trends and consolidation in injectable drugs and contract services, to innovation in manufacturing and generics and their potential role in improving global access to medicine.

Piramal’s Sharma discusses market trends including growth in outsourcing, in generic injectables, and overall market consolidation, as compliance and quality demands may drive some smaller companies out of business.

Dilip Shah examines the potential impact of the U.S. Trade Promotion Authority Bill, TPA 2015, which would give the President the right to fast track huge trade deals.  

Prabir Basu begins his essay on innovation by asking a question posed seven years ago by IBM:  what can pharma learn from the automotive industry?  Basu sees many similarities between pharma’s situation today and where carmakers were back in 2008, with inefficiencies in manufacturing; older plants and infrastructure; lack of innovation; and insufficient customer focus.

IMS’ Shepperd begins his op-ed by sketching a utopian world where there was total freedom of access to safe, effective and affordable medicines.  That picture remains a dream, given a reality where Europe is mandating price cuts for pharmaceuticals across the board, both name-brand and generic drugs.  In addition, more costs are shifting to the consumer.

Download Part 3 of the report here. 





External Link - CPhI annual rep 2015 v9f part3.pdf

Related Videos
Related Content